Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haptoglobin to Prevent Hemolysis-Related Organ Damage in Cardiovascular Surgery
jRCT1051210147Completed
- Sponsor
- Grants-in-Aid for Scientific Research
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of haptoglobin in Cardiac valve disease (VHD), aortic aneurysm, aortic dissection and 3 more (2 arms), sponsored by Grants-in-Aid for Scientific Research. Primary endpoint: Change in serum creatinine within 48 hours after surgery. Started Mar 2022; status: completed.
02
Drugs
haptoglobin
03
Conditions
Cardiac valve disease (VHD)aortic aneurysmaortic dissectioncoronary arteriosclerosishemolysis
Beyond the preview
Go deeper on jRCT1051210147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051210147.